SkinHealth Systems (SKIN) Panoramica del titolo
SkinHealth Systems Inc. è un'azienda globale di estetica medica che offre un ecosistema integrato di soluzioni clinicamente testate nelle Americhe, nell'Asia-Pacifico, in Europa, nel Medio Oriente, in Africa, in Canada e in America Latina. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
SKIN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di SkinHealth Systems Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.71 |
| Massimo di 52 settimane | US$2.69 |
| Minimo di 52 settimane | US$0.55 |
| Beta | 0.99 |
| Variazione di 1 mese | -36.47% |
| Variazione a 3 mesi | 21.59% |
| Variazione di 1 anno | -55.65% |
| Variazione a 3 anni | -90.04% |
| Variazione a 5 anni | -96.58% |
| Variazione dall'IPO | -93.49% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 10
SKIN: Fair Outlook Weighs Competitive Pressure Against New FDA Clearances
Analysts have trimmed their price target on SkinHealth Systems to $1.00 from $1.50, citing updated assumptions that reflect softer modeled revenue growth, a lower fair value estimate, modestly improved profit margin expectations, and a reduced future P/E multiple in light of ongoing competitive pressures in the lower end of the market. Analyst Commentary on SkinHealth Systems Recent research commentary on SkinHealth Systems points to a more cautious stance, with several bearish analysts revisiting their models after the latest quarterly update and trimming valuation assumptions to reflect ongoing competitive and execution risks.
Aggiornamento narrativa • Jun 26
SKIN: Clearer Device Positioning And Margins Will Support Future Upside
Analysts have reduced the SkinHealth Systems price target to $2.00 from $3.50, citing updated models that reflect higher discount rates, softer revenue growth assumptions, lower expected profit margins, and a much higher projected future P/E multiple in light of rising competitive pressures across the beauty device market. Analyst Commentary Recent Street research on SkinHealth Systems highlights that analysts are recalibrating their expectations while still pointing to potential areas where the stock could regain investor interest.
Aggiornamento narrativa • Jun 06
SKIN: Future Returns Will Hinge On Delivering FY26 EBITDA Under Competitive Pressure
Narrative Update on SkinHealth Systems Analysts have trimmed the SkinHealth Systems price target from $2.50 to $2.00, citing updated models that factor in recent earnings, ongoing competitive pressure at the lower end of the market, and adjusted long term assumptions for revenue growth, profit margins, discount rate and future P/E. Analyst Commentary Recent research commentary around SkinHealth Systems centers on recalibrated price targets, revised models following quarterly updates, and an ongoing focus on how the company manages competitive pressure at the lower end of the market.Recent updates
Aggiornamento narrativa • Jul 10
SKIN: Fair Outlook Weighs Competitive Pressure Against New FDA Clearances
Analysts have trimmed their price target on SkinHealth Systems to $1.00 from $1.50, citing updated assumptions that reflect softer modeled revenue growth, a lower fair value estimate, modestly improved profit margin expectations, and a reduced future P/E multiple in light of ongoing competitive pressures in the lower end of the market. Analyst Commentary on SkinHealth Systems Recent research commentary on SkinHealth Systems points to a more cautious stance, with several bearish analysts revisiting their models after the latest quarterly update and trimming valuation assumptions to reflect ongoing competitive and execution risks.Aggiornamento narrativa • Jun 26
SKIN: Clearer Device Positioning And Margins Will Support Future Upside
Analysts have reduced the SkinHealth Systems price target to $2.00 from $3.50, citing updated models that reflect higher discount rates, softer revenue growth assumptions, lower expected profit margins, and a much higher projected future P/E multiple in light of rising competitive pressures across the beauty device market. Analyst Commentary Recent Street research on SkinHealth Systems highlights that analysts are recalibrating their expectations while still pointing to potential areas where the stock could regain investor interest.Aggiornamento narrativa • Jun 06
SKIN: Future Returns Will Hinge On Delivering FY26 EBITDA Under Competitive Pressure
Narrative Update on SkinHealth Systems Analysts have trimmed the SkinHealth Systems price target from $2.50 to $2.00, citing updated models that factor in recent earnings, ongoing competitive pressure at the lower end of the market, and adjusted long term assumptions for revenue growth, profit margins, discount rate and future P/E. Analyst Commentary Recent research commentary around SkinHealth Systems centers on recalibrated price targets, revised models following quarterly updates, and an ongoing focus on how the company manages competitive pressure at the lower end of the market.Aggiornamento narrativa • Apr 21
SKIN: Future Returns Will Rely On FY26 EBITDA Delivery Despite Macro Pressures
Analysts trimmed Beauty Health's price target by $0.15 to $1.50, citing updated models after Q4 results where revenue was lower but ahead of expectations, FY26 EBITDA guidance points to upside versus current Street estimates, and softer near term distributor orders tied to macro pressure. Analyst Commentary Recent commentary highlights a mixed read on Beauty Health, with analysts weighing long term profit guidance against near term demand headwinds and a slightly lower price target of US$1.50.Aggiornamento narrativa • Apr 07
SKIN: Future Returns Will Be Supported By FY26 EBITDA Guidance Delivery
Analysts have trimmed Beauty Health's price target by $0.15 to $1.50 as they refresh models after Q4 results that showed revenue down but ahead of expectations, with updated EBITDA guidance for FY26 and softer near term distributor ordering under macro pressure helping to shape their outlook. Analyst Commentary Recent research paints a mixed picture for Beauty Health, with analysts updating models after Q4 and revisiting fair value as they factor in near term pressure on distributor orders alongside longer term profitability targets.Aggiornamento narrativa • Mar 24
SKIN: Future Returns Will Be Supported By FY26 EBITDA Upside Potential
The analyst price target for Beauty Health has been reduced by $0.15 to $1.50, as analysts factor in softer near term distributor ordering after Q4 revenue came in down but ahead of expectations, alongside FY26 EBITDA guidance that they view as implying roughly 20% upside versus the Street. Analyst Commentary Analysts are recalibrating their views on Beauty Health after the Q4 report, focusing on the tension between softer near term trends and what they see in the company’s longer term EBITDA guidance.Aggiornamento narrativa • Mar 10
SKIN: Updated Governance And Margin Execution Will Support Future Upside
Analysts have nudged their price target for Beauty Health higher to $3.50, citing slightly stronger assumptions around revenue growth, profit margins, and a modestly lower discount rate reflected in a small adjustment to the future P/E. Analyst Commentary Recent research points to a more constructive tone around Beauty Health, with price targets and ratings framed around what analysts see as the company’s ability to execute on its current plan rather than any major shift in its business model.Aggiornamento narrativa • Feb 24
SKIN: Higher Assumed P/E And Margin Execution Will Support Future Upside
Analysts have nudged their price targets on Beauty Health higher to $3.38, reflecting updated views on risk, modest revenue expectations, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Beauty Health has focused on how to balance risk, valuation, and execution, with some bullish analysts pointing to conditions they believe could support the higher US$3.38 price target.Articolo di analisi • Feb 12
It's Down 30% But The Beauty Health Company (NASDAQ:SKIN) Could Be Riskier Than It Looks
The Beauty Health Company ( NASDAQ:SKIN ) shareholders won't be pleased to see that the share price has had a very...Aggiornamento narrativa • Feb 08
SKIN: Execution On Updated Margin Plan Will Support Future Upside
Analysts have nudged their price target on Beauty Health higher to around a fair value of US$3.38 per share, citing modest adjustments to growth, margins and future P/E assumptions reflected in recent TD Cowen and Jefferies research. Analyst Commentary Recent Street research around Beauty Health has centered on modestly higher valuation markers and a reaffirmation of a more wait and see stance on the shares.Articolo di analisi • Feb 06
Is Beauty Health (NASDAQ:SKIN) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento narrativa • Jan 25
SKIN: Improved Execution And Buyback Progress Will Support Future Upside
Analysts have inched their average price target for Beauty Health higher by US$0.15, reflecting updated views on growth, margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish analysts are framing the US$0.15 increase in the average price target as a sign that recent updates to growth and margin expectations still support the current valuation, even with a slightly lower assumed future P/E multiple.Aggiornamento narrativa • Jan 11
SKIN: Future Returns Will Be Supported By Stable Margins And Completed Buyback Program
Analysts have modestly adjusted their price target on Beauty Health, citing small tweaks to the discount rate, revenue growth expectations, profit margin assumptions and forward P/E multiples. Together, these changes support a refined valuation framework rather than a major reset in outlook.Aggiornamento narrativa • Dec 27
SKIN: Share Repurchase And New CEO Are Expected To Drive Upside
Analysts have modestly raised their price target on Beauty Health, reflecting a move in fair value from approximately 2.00 dollars to about 3.38 dollars. They factor in slightly stronger long term revenue growth expectations alongside a higher future earnings multiple, partially offset by a marginally lower projected profit margin and a slightly higher discount rate.Aggiornamento narrativa • Dec 13
SKIN: Future Returns Will Be Driven By Improved Device Churn Management
Analysts modestly raised their price target on Beauty Health to $2.50 from $2.00, citing early evidence that the CEO's reset is helping manage device churn, spur consumables innovation, and deepen engagement across its 35,000 strong installed base. Analyst Commentary Analysts are reacting to the updated outlook with a balanced tone, reflecting both improving fundamentals and lingering execution risks that cap near term upside.Aggiornamento narrativa • Nov 29
SKIN: Future Growth Will Be Driven By Improved Churn Management
Analysts have raised their price target for Beauty Health from $2.00 to $2.50. They cite improved management of device sales, consumables innovation, and deeper provider engagement as key factors supporting the company's outlook.Articolo di analisi • Nov 27
Is There An Opportunity With The Beauty Health Company's (NASDAQ:SKIN) 35% Undervaluation?
Key Insights The projected fair value for Beauty Health is US$2.24 based on 2 Stage Free Cash Flow to Equity Current...Aggiornamento narrativa • Nov 15
SKIN: Future Revenue Will Be Driven By Improved Device Sales Management
Analysts have increased their price target for Beauty Health from $2.00 to $2.50. They cite improved device sales management, innovation in consumables, and deeper provider engagement as drivers for this positive outlook.Articolo di analisi • Oct 14
The Market Doesn't Like What It Sees From The Beauty Health Company's (NASDAQ:SKIN) Revenues Yet As Shares Tumble 40%
The Beauty Health Company ( NASDAQ:SKIN ) shares have had a horrible month, losing 40% after a relatively good period...Aggiornamento narrativa • Sep 20
Premium Beauty Markets Will Face Risks And Rewards
Beauty Health’s consensus price target has increased notably as the market now assigns a higher future P/E multiple despite a slight decline in net profit margin, reflecting increased investor optimism and raising the fair value estimate from $1.88 to $2.17. What's in the News Completed repurchase of 10,350,749 shares (7.81%) for $30.18 million; no shares repurchased in the latest tranche.Articolo di analisi • Aug 30
The Beauty Health Company's (NASDAQ:SKIN) 30% Price Boost Is Out Of Tune With Revenues
The The Beauty Health Company ( NASDAQ:SKIN ) share price has done very well over the last month, posting an excellent...Aggiornamento narrativa • Aug 08
Premium Beauty Markets Will Face Risks And Rewards
The upward revision in Beauty Health’s consensus price target to $1.75 is primarily driven by a substantial increase in revenue growth forecasts and a lower discount rate, signaling improved growth expectations and a more favorable risk profile. What's in the News Company updated earnings guidance, projecting Q3 net sales of $65–$70 million and full-year net sales of $285–$300 million, citing strong first half performance.Articolo di analisi • May 11
Analysts Are Updating Their The Beauty Health Company (NASDAQ:SKIN) Estimates After Its First-Quarter Results
A week ago, The Beauty Health Company ( NASDAQ:SKIN ) came out with a strong set of first-quarter numbers that could...Articolo di analisi • Apr 11
The Beauty Health Company (NASDAQ:SKIN) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, The Beauty Health Company ( NASDAQ:SKIN ) shares are down a considerable 26% in...
Nuova narrativa • Apr 02
Sales Execution And Hydralock Booster Launch Will Strengthen Future Prospects
Operational improvements and strategic market positioning are set to enhance profitability and boost revenue growth.Articolo di analisi • Mar 14
The Beauty Health Company (NASDAQ:SKIN) Analysts Just Cut Their EPS Forecasts Substantially
Market forces rained on the parade of The Beauty Health Company ( NASDAQ:SKIN ) shareholders today, when the analysts...Articolo di analisi • Feb 27
Is Beauty Health (NASDAQ:SKIN) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Dec 27
The Beauty Health Company (NASDAQ:SKIN) Doing What It Can To Lift Shares
The Beauty Health Company's ( NASDAQ:SKIN ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a buy right...Articolo di analisi • Oct 18
Health Check: How Prudently Does Beauty Health (NASDAQ:SKIN) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Aug 06
Positive Sentiment Still Eludes The Beauty Health Company (NASDAQ:SKIN) Following 33% Share Price Slump
To the annoyance of some shareholders, The Beauty Health Company ( NASDAQ:SKIN ) shares are down a considerable 33% in...Rendimenti per gli azionisti
| SKIN | US Personal Products | US Mercato | |
|---|---|---|---|
| 7D | 4.3% | 1.0% | 5.5% |
| 1Y | -55.6% | -12.4% | 20.8% |
Ritorno vs Industria: SKIN ha avuto una performance inferiore rispetto al US Personal Products che ha registrato un rendimento -12.4 % nell'ultimo anno.
Rendimento vs Mercato: SKIN ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20.8 % nell'ultimo anno.
Volatilità dei prezzi
| SKIN volatility | |
|---|---|
| SKIN Average Weekly Movement | 21.1% |
| Personal Products Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di SKIN è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di SKIN è aumentata da 14% a 21% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1997 | 613 | Pedro Malha | www.skinhealthsystems.com |
SkinHealth Systems Inc. è un'azienda globale di estetica medica che offre un ecosistema integrato di soluzioni clinicamente testate nelle Americhe, nell'Asia-Pacifico, in Europa, nel Medio Oriente, in Africa, in Canada e in America Latina. Il prodotto di punta dell'azienda è HydraFacial, che migliora la pelle per pulirla, estrarla e idratarla con soluzioni e sieri proprietari. L'azienda offre anche i dispositivi Syndeo, che sono sistemi di erogazione progettati per collegare i fornitori alle preferenze dei consumatori e creare un'esperienza più personalizzata; i materiali di consumo, come le punte monouso, le soluzioni e i sieri utilizzati per fornire un trattamento idrofacciale; SkinStylus SteriLock Microsystem, un dispositivo di microneedling e nanoneedling utilizzato per il trattamento dell'aspetto delle cicatrici ipertrofiche chirurgiche o traumatiche sull'addome e delle cicatrici da acne sul viso nei tipi di pelle Fitzpatrick I, II e III; e le soluzioni peptidiche Keravive e gli spray da portare a casa per il trattamento della salute del cuoio capelluto.
SkinHealth Systems Inc. Riepilogo dei fondamenti
| SKIN statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$91.39m |
| Utili (TTM) | -US$6.54m |
| Ricavi(TTM) | US$296.12m |
0.3x
Rapporto P/S-14.0x
Rapporto P/ESKIN è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SKIN Conto economico (TTM) | |
|---|---|
| Ricavi | US$296.12m |
| Costo del fatturato | US$103.90m |
| Profitto lordo | US$192.22m |
| Altre spese | US$198.77m |
| Utili | -US$6.54m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 06, 2026
| Utile per azione (EPS) | -0.05 |
| Margine lordo | 64.91% |
| Margine di profitto netto | -2.21% |
| Rapporto debito/patrimonio netto | 623.1% |
Come si è comportato SKIN nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/06 06:49 |
| Prezzo dell'azione a fine giornata | 2026/08/05 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
SkinHealth Systems Inc. è coperta da 11 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Bruce Jackson | Benchmark Company |
| Navann Ty Dietschi | BNP Paribas |
| Susan Anderson | Canaccord Genuity |